Online Pharmacies To Witness Rapid Growth In The PBC Therapeutics Market, Valued At $683.95 Million In 2022

 


The global Primary Biliary Cholangitis (PBC) Therapeutics market is poised for substantial growth, with a valuation of $683.95 million in 2022 and an anticipated surge to approximately $1.4 billion by 2032, driven by a notable CAGR of 7.1% from 2023 to 2032. PBC Therapeutics encompass a spectrum of treatment options tailored to manage and address primary biliary cholangitis, a chronic autoimmune liver ailment primarily impacting the small bile ducts within the liver.

Key growth drivers encompass a surge in primary biliary cholangitis cases and a growing awareness of the ailment. The annual PBC incidence varies from 0.23 to 5.31 per 100,000 individuals, with Japan alone harboring over 37,000 PBC patients.

Significant advancements in therapeutics, coupled with ongoing global research and development efforts in PBC therapeutics, are propelling market expansion. Notably, promising treatments like Setanaxib, presently in Phase III clinical trials for PBC, are kindling interest in advanced therapies.

The market offers lucrative growth opportunities for key players, including heightened awareness of the merits of PBC therapeutics, strategic acquisitions, and mounting global demand for these treatments. Furthermore, investments in research and development, along with escalated production, are poised to contribute substantially to market growth.

Key market segments encompass diverse drug types (primary and secondary drugs) and distribution channels (hospital pharmacies, drug stores, and online pharmacies). The primary drug segment is anticipated to reach $1,196.3 million by 2032, marked by a CAGR of 7.3% during the forecast period. Notably, online pharmacies are expected to be the fastest-growing segment, with an 8.6% CAGR. Presently, North America dominates the PBC therapeutics market and is expected to maintain its supremacy. Meanwhile, Asia-Pacific is predicted to witness the highest CAGR of 8.5% during the forecast period.

Key market dynamics include the upswing in primary biliary cholangitis cases and robust research and development endeavors. On the flip side, challenges include the paucity of early diagnosis and limited treatment options, while opportunities lie in the adoption of key strategies within the market.

Read More - https://www.techdogs.com/tech-news/pr-newswire/online-pharmacies-to-witness-rapid-growth-in-the-pbc-therapeutics-market-valued-at-68395-million-in-2022

Comments

Post a Comment

Popular posts from this blog

Orlagh Neary, Former VP Of Quantum Ecosystem Engagement And GTM At Microsoft On Building Scalable And Safe AI And Quantum

Image
  What if the future of computing isn’t about picking sides—AI, LLMs, or quantum—but about blending them into a unified, game-changing force? In this compelling episode of Discover Dialogues , host Nikhil Sonawane sits down with Orlagh Neary, whose remarkable career has spanned continents, technologies, and industries. From AI to developer platforms to localization, Orlagh now spearheads Microsoft’s Quantum and AI Ecosystem Engagement & GTM strategy. She also serves on the board of Cambrian Futures and advises UNESCO’s International Year of Quantum—making her a key voice in turning today’s emerging tech into tomorrow’s foundation. What makes Orlagh’s approach truly stand out is her ability to align frontier technologies with enterprise priorities. She explains how AI (pattern recognition), LLMs (language), and quantum computing (scale) aren't separate silos—they’re a collaborative “dream team” poised to revolutionize sectors from healthcare to logistics. 👉 Read more about this...
Read more

Varun Srinivas Founder & CEO of Therix.ai and Co-Founder at Coditas on Building Real-World AI Solutions

Image
  In this episode of Discover Dialogues , Vikramsinh Ghatge, Sr. Marketing Director and Editor-in-Chief at TechDogs , sits down with Varun Srinivas, Founder & CEO of Therix.ai and Co-Founder at Coditas, to explore what it truly takes to turn AI prototypes into scalable, real-world solutions. Over the past decade, Varun has been at the forefront of transforming solid engineering principles into practical AI deployments. In this candid conversation, he breaks away from buzzwords and highlights how AI must be built with people, not just algorithms, at the center. The discussion kicks off with an eye-opening statement: “AI isn’t coming for your job—but someone using AI might.” Varun quickly dismantles the fear-driven narratives surrounding AI and instead urges leaders to focus on empowering teams, fostering experimentation, and applying disciplined engineering practices. One standout topic is the rise of “vibe coding”—the fast, intuitive, generative AI-driven approach to developme...
Read more

MediaTek Vs. Snapdragon: Which Chipset Performs Better?

Image
  Smartphone makers face a key choice: MediaTek or Snapdragon ? Both brands power millions of devices but offer different strengths. Quick Intro Mobile processors, or SoCs, are the brains of smartphones—combining CPUs, GPUs, modems, and AI engines into one chip. The Rivals MediaTek (Taiwan, 1997) powers budget and mid-range phones with its Dimensity series, offering strong AI, good graphics, and 5G at great value. Snapdragon (Qualcomm, USA, 1985) dominates high-end phones with custom CPUs, Adreno GPUs, advanced AI, and superior 5G. By 2025, MediaTek leads in market share at 46%, compared to Qualcomm’s 35%. 👉 Full Comparison: MediaTek vs. Snapdragon Head-to-Head Customization : MediaTek uses standard ARM designs; Snapdragon builds custom CPUs and GPUs. AI & Gaming : Snapdragon leads but MediaTek is closing in. Power & 5G : Both offer 4nm chips, but Snapdragon has better global 5G and advanced camera support. Value : MediaTek wins on affordability; Snapdragon ex...
Read more